Our mission - is to facilitate the transition of the Russian pharmaceutical market to develop into mature, be a guide on the course of development of the potential of all the pharmaceutical market participants, thereby improving the quality of life for the end user and society in general. Despite the relatively high susceptibility to Russia's external economic and financial risks, imbalances in the domestic policy and great social disparities, the pharmaceutical market in Russia has had a stable positive growth for the last few years.
From January 1, 2018, a resolution of the Government of the Russian Federation No. 1397 dated November 15, 2017 "On the Specifics of the Description of Medicinal Products for Medical Purposes, which are the Object of Procurement for the Provision of State and Municipal Needs", enters into force. In the opinion of the advisor to the Director of the Institute of Public Procurement Anna Ermakova (pictured), customers, suppliers and manufacturers of medicines need to ask clarification from the regulators in order to bring the practice of applying this ruling to a comprehensible and adequate format for medical purposes.
AstraZeneca plans to spend within three years within the SPIC the localization of the production of ten medicines, six of which have no analogues in the Russian Federation. As Irina Panarina, general director of AstraZeneca, Russia and Eurasia has informed, from the end of 2019 these preparations will begin to enter the commercial market.
The manual "Clinical Research Management" describes a methodology for the effective management of a project for finding, developing and marketing pharmaceuticals, starting with the search for promising chemical compounds, preclinical testing of candidate substances, clinical trials of candidate drugs, pharmacovigilance, data management, analysis of the data obtained, compilation of a final report on the study, obtaining a registration certificate, publication of the results Tats, to organizing post-marketing safety studies, conducting non-interventional and pharmaco-epidemiologic studies, as well as the quality assurance process of the audit, and authorized health authority inspections, creation of standard operating procedures, archiving research documents.
According to MilTech, the global market for orphan drugs by the end of 2025 may exceed $ 300 billion. Such data is contained in the Global Industry Analysis, Size, Share, Volume, Growth, Trends, and Forecast 2017-2025 reports.
In 2018, a significant increase in the cost of medical care at the expense of the OMS system - an increase of 333 billion rubles (an increase of 21.5 percent). This will allow to raise tariffs for all types of medical care within the framework of the OSI Basic Program and will provide an opportunity to provide citizens with high-quality and affordable medical care as well as to achieve the wages of medical workers in accordance with the May Decrees of the President of the Russian Federation.
Happy New Year and Merry Christmas, dear readers, colleagues and partners !!! Let the next year become special for you, bring to life the most daring ideas and cherished dreams. Fill every day with happiness, joy and love, surround with care and warmth. Health, good, love to you and your loved ones!
On a position in Market Access, pharmaceutical companies prefer to hire employees with experience in the industry, ready to study and try to apply modern models of interaction between pharmaceutical business and the state, says consultant of the practice "Medicine and Pharmaceuticals" of Hays recruiting company in Russia Marina Dmitrieva.